selonsertib

Gilead Sciences, Inc. (NASDAQ: GILD) is facing another setback, as its non-alcoholic steatohepatitis, or NASH, candidate Selonsertib flunked in a late-stage study. Stellar Trial's Dimmed Results Gilead said the STELLAR-4 study that evaluated the safety and efficacy of Selonsertib in patients...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading lower by more than 2 percent Wednesday morning after the company's first quarter earnings and revenue fell short of what analysts were expecting. Although Gilead's numbers point to a top-and-bottom line beat, Barclays' Geoff...